NHS to offer weight-loss jab Wegovy to combat secondary heart attacks and strokes
Wegovy to be Prescribed for Cardiovascular Protection
The weight-loss drug Wegovy, also known as semaglutide, will be made available on the NHS to a significant cohort of patients in England. This initiative targets over one million individuals who have previously suffered a heart attack or stroke, or who have severe circulation problems in their legs, and are also overweight.
NICE has endorsed the weekly injection as a crucial supplementary measure for these patients, complementing their existing heart medications, such as statins, and a healthy lifestyle. This decision is underpinned by robust clinical trial data indicating a 20% reduction in the risk of future cardiovascular events when Wegovy is used alongside current treatments.
Evidence Beyond Weight Loss
Crucially, the benefits of Wegovy were observed early in clinical trials, prior to substantial weight loss. This suggests the drug exerts a direct protective effect on the heart and blood vessels, rather than solely through its weight-reducing properties. This revelation is a significant factor in NICE's recommendation.
Individuals meeting the Body Mass Index (BMI) criteria for being overweight or obese (BMI of 27 or higher) will be eligible. Prescriptions will be issued by GPs or specialists who will assess suitability. Patients will be able to self-administer the medication at home using a pen injector device.
Rollout and Considerations
The rollout of Wegovy on the NHS is anticipated to commence this summer. While the drug effectively suppresses appetite by mimicking the GLP-1 hormone, thereby aiding weight loss, some individuals may experience side effects such as bloating, nausea, or discomfort. Furthermore, doctors will continue to emphasise the importance of lifestyle changes, including a balanced diet and regular exercise, to ensure sustained health benefits.
Currently, NHS treatment with Wegovy is limited to two years, with ongoing studies into its long-term effects. Concerns remain about potential muscle mass reduction, highlighting the importance of incorporating physical activity, particularly resistance training, into patient management plans.
